Servier has expanded its collaboration agreement with Cellectis to develop and commercialise allogenic CAR-T products targeting CD19, including rights to ALLO-501A. The original agreement was signed in 2014 for the development of UCART19 as well as five other product candidates targeting solid tumours. As part of the new agreement, Cellectis regains control over the five undisclosed allogeneic CAR-T cell targets while Servier pays an additional €25 M (US$27.6 M) and broadens its immunotherapy pipeline beyond UCART19.